These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36174614)

  • 1. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
    de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
    Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
    Mavinkurve-Groothuis AMC; de Baat EC; Feijen EAM; Kremer LCM; Armenian SH; Mulder RL; van Dalen EC
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30604. PubMed ID: 37505793
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
    Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cardiotoxicity among survivors of childhood cancer.
    Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
    Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
    Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
    Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS; Scott LJ
    Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing cardiac toxicity in children with acute myeloid leukemia.
    Narayan HK; Getz KD; Leger KJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
    Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
    Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in adult survivors of childhood cancer.
    Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
    Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.